METHODS OF MYOCARDIAL PERFUSION IMAGING
Granted: October 4, 2012
Application Number:
20120251440
The present invention provides a method for identifying and using partial adenosine A2A receptor agonists that are useful as adjuncts in myocardiological perfusion imaging.
INHALABLE AZTREONAM LYSINATE FORMULATION FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
Granted: October 4, 2012
Application Number:
20120251585
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a…
MODULATORS OF TOLL-LIKE RECEPTOR 7
Granted: September 27, 2012
Application Number:
20120244121
The present invention includes therapeutic methods that include the administration of a compound of Formula I or II: or a pharmaceutically acceptable salt, solvate, and/or ester thereof, to a subject in need of such, and therapeutic methods that include the administration of such compounds with at least one additional active agent.
MODULATORS OF PHARMACOKINETIC PROPERTIES OF THERAPEUTICS
Granted: September 20, 2012
Application Number:
20120237478
The present application provides for a compound of Formula IV, or a pharmaceutically acceptable salt, solvate, and/or ester thereof, compositions containing such compounds, therapeutic methods that include the administration of such compounds, and therapeutic methods and include the administration of such compounds with at least one additional therapeutic agent.
PROCESS AND INTERMEDIATES FOR PREPARING INTEGRASE INHIBITORS
Granted: September 20, 2012
Application Number:
20120238758
The invention provides synthetic processes and synthetic intermediates that can be used to prepare 4-oxoquinolone compounds having useful integrase inhibiting properties.
CRYSTALLINE FORMS OF (3R, 3AS, 6AR) - HEXAHYDROFURO [2,3-B] FURAN-3-YL (1S,2R) - (1-{4-[ (DIETHOXYPHOSPHORYL) METHOXY] PHENY1}-3-HYDROXY-4- [4-METHOXY-N- (2-METHYLPROPYL) BENZENESUL - FONAMIDO] BUTAN-2-YL) CARBAMATE
Granted: September 13, 2012
Application Number:
20120232038
The present inventions provides crystalline forms of (3R,3aS,6aR)-hexahydrofuro[2,3-b]furan-3-yl (1S,2R)-(1-{4-[(diethoxyphosphoryl)methoxy]phenyl}-3-hydroxy-4-[4-methoxy-N-(2-methylpropyl)benzenesulfonamido]butan-2-yl)carbamate, methods of preparing the crystalline forms, pharmaceutical compositions containing the crystalline forms, and therapeutic uses thereof.
ANTI-RSV COMPOUNDS
Granted: August 2, 2012
Application Number:
20120196846
The present invention relates to anti-RSV compounds of Formula (I) and methods for use of the compounds in the treatment and prevention of RSV infection.
ANTIVIRAL COMPOUNDS
Granted: July 26, 2012
Application Number:
20120190866
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
INHIBITORS OF FLAVIVIRIDAE VIRUSES
Granted: June 21, 2012
Application Number:
20120156166
Provided are compounds of Formula I: and pharmaceutically acceptable salts and esters thereof. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections.
ANTIVIRAL COMPOUNDS
Granted: June 21, 2012
Application Number:
20120157404
The invention is related to anti-viral compounds, compositions containing such compounds, and therapeutic methods that include the administration of such compounds, as well as to processes and intermediates useful for preparing such compounds.
2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Granted: May 3, 2012
Application Number:
20120107274
Provided are methods for treating Orthomyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein R2 is halogen. The compounds, compositions, and methods provided are particularly useful for the treatment of Human Influenza virus infections.
CRYSTALLINE PYRIDAZINE COMPOUND
Granted: May 3, 2012
Application Number:
20120108601
A crystalline compound of formula (1) and its salts and solvates are provided for the treatment or prophylaxis of hepatitis C virus infections Methods of making and formulating crystalline compound (1) are provided.
INHALABLE AZTREONAM FOR TREATMENT AND PREVENTION OF PULMONARY BACTERIAL INFECTIONS
Granted: April 19, 2012
Application Number:
20120093890
A method and a composition for treatment of pulmonary bacterial infections caused by gram-negative bacteria suitable for treatment of infection caused by Escherichia coli, Klebsiella pneumoniae, Klebsiella oxytoca, Pseudomonas aeruginosa, Haemophilus influenzae, Proteus mirabilis, Enterobacter species, Serratia marcescens as well as those caused by Burkholderia cepacia, Stenotrophomonas maltophilia, Alcaligenes xylosoxidans, and multidrug resistant Pseudomonas aeruginosa, using a…
TRIAZOLOPYRIDINONE DERIVATIVES FOR USE AS STEAROYL CoA DESATURASE INHIBITORS
Granted: March 15, 2012
Application Number:
20120065227
The present invention discloses triazolopyridinone derivatives for use as inhibitors of stearoyl-CoA desaturase having the structure of Formula I: The compounds are useful in treating and/or preventing various human diseases, mediated by stearoyl-CoA desaturase (SCD) enzymes, especially diseases related to abnormal lipid levels, cardiovascular disease, diabetes, obesity, metabolic syndrome and the like.
INHIBITORS OF HEPATITIS C VIRUS
Granted: March 1, 2012
Application Number:
20120053148
The present application includes novel inhibitors of HCV, compositions containing such compounds, therapeutic methods that include the administration of such compounds.
CYCLOALKYLIDENE AND HETEROCYCLOALKYLIDENE INHIBITOR COMPOUNDS
Granted: February 23, 2012
Application Number:
20120045412
The present invention provides a compound of general Formula (I) having histone deacetylase (HDAC) inhibitory activity, a pharmaceutical composition comprising the compound, and a method useful to treat diseases using the compound.
METHODS AND COMPOUNDS FOR TREATING PARAMYXOVIRIDAE VIRUS INFECTIONS
Granted: February 2, 2012
Application Number:
20120027752
Provided are methods for treating Paramyxoviridae virus infections by administering ribosides, riboside phosphates and prodrugs thereof, of Formula I: wherein the 1? position of the nucleoside sugar is substituted. The compounds, compositions, and methods provided are particularly useful for the treatment of Human parainfluenza and Human respiratory syncytial virus infections.
1'-SUBSTITUTED-CARBA-NUCLEOSIDE PRODRUGS FOR ANTIVIRAL TREATMENT
Granted: January 26, 2012
Application Number:
20120020921
Provided are prodrugs of pyrrolo[1,2-f][1,2,4]triazin-7-yl nucleoside phosphates wherein the 1? position of the nucleoside sugar is substituted with CN. The compounds, compositions, and methods provided are useful for the treatment Hepatitis C infections.
2'-FLUORO SUBSTITUTED CARBA-NUCLEOSIDE ANALOGS FOR ANTIVIRAL TREATMENT
Granted: January 12, 2012
Application Number:
20120009147
Provided are select imidazo[1,2-f][1,2,4]triazinyl nucleosides, nucleoside phosphates and prodrugs thereof, wherein the 2? position of the nucleoside sugar is substituted with halogen and carbon substituents. The compounds, compositions, and methods provided are useful for the treatment of Flaviviridae virus infections, particularly hepatitis C infections caused by both wild type and mutant strains of HCV.
PYRAZOLO[1,5-A]PYRIMIDINES FOR ANTIVIRAL TREATMENT
Granted: January 5, 2012
Application Number:
20120003215
The invention provides compounds of Formula I or Formula II: or a pharmaceutically acceptable salt or ester, thereof, as described herein. The compounds and compositions thereof are useful for treating Pneumovirinae virus infections. The compounds, compositions, and methods provided are particularly useful for the treatment of Human respiratory syncytial virus infections.
